Literature DB >> 21559819

Estrogen and thrombosis: controversies and common sense.

Thomas G DeLoughery1.   

Abstract

Soon after the introduction of hormonal oral contraceptive agents reports of thrombotic complications appeared. In the past several decades, large epidemiological studies helped defined these risks for both arterial and venous complications. Clinicians can assess a patient's risk of thrombosis by both composition of the agent and patients' personal risk factors. For women with bleeding disorders these prothrombotic changes can help decrease bleeding complications. There is now also abundant data on future management of patients with estrogen related thrombosis.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21559819     DOI： 10.1007/s11154-011-9178-0

Source DB:  PubMed          Journal:  Rev Endocr Metab Disord        ISSN： 1389-9155            Impact factor:   6.514


  63 in total

Review 1.  Prescribing oral contraceptives for women older than 35 years of age.

Authors:  Christine Seibert; Ellen Barbouche; Julie Fagan; Erane Myint; Tosha Wetterneck; Melaura Wittemyer
Journal:  Ann Intern Med       Date:  2003-01-07       Impact factor: 25.391

2.  Deep vein thrombosis and pulmonary embolism reported in the Prescription Event Monitoring Study of Yasmin.

Authors:  Hilary M Pearce; Deborah Layton; Lynda V Wilton; Saad A W Shakir
Journal:  Br J Clin Pharmacol       Date:  2005-07       Impact factor: 4.335

3.  Oral contraceptives and the risk of myocardial infarction.

Authors:  B C Tanis; M A van den Bosch; J M Kemmeren; V M Cats; F M Helmerhorst; A Algra; Y van der Graaf; F R Rosendaal
Journal:  N Engl J Med       Date:  2001-12-20       Impact factor: 91.245

4.  Oral contraceptives and venous thromboembolism.

Authors:  Nick Dunn
Journal:  BMJ       Date:  2009-08-13

5.  Probable drug interaction between warfarin and hormonal contraceptives.

Authors:  Michelle M Zingone; Alexander B Guirguis; Anita Airee; Diana Cobb
Journal:  Ann Pharmacother       Date:  2009-11-24       Impact factor: 3.154

Review 6.  The use of newer progestins for contraception.

Authors:  Regine Sitruk-Ware; Anita Nath
Journal:  Contraception       Date:  2010-05-11       Impact factor: 3.375

7.  Population-based study of risk of venous thromboembolism associated with various oral contraceptives.

Authors:  R D Farmer; R A Lawrenson; C R Thompson; J G Kennedy; I R Hambleton
Journal:  Lancet       Date:  1997-01-11       Impact factor: 79.321

8.  Effects of the contraceptive patch, the vaginal ring and an oral contraceptive on APC resistance and SHBG: a cross-over study.

Authors:  K Fleischer; H A van Vliet; F R Rosendaal; J Rosing; S Tchaikovski; F M Helmerhorst
Journal:  Thromb Res       Date:  2008-09-30       Impact factor: 3.944

9.  Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception.

Authors: 
Journal:  Lancet       Date:  1995-12-16       Impact factor: 79.321

10.  Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception.

Authors: 
Journal:  Lancet       Date:  1995-12-16       Impact factor: 79.321
View more
  8 in total

1.  The sexual dimorphism associated with pulmonary hypertension corresponds to a fibrotic phenotype.

Authors:  Olga Rafikova; Ruslan Rafikov; Mary Louise Meadows; Archana Kangath; Danny Jonigk; Stephen M Black
Journal:  Pulm Circ       Date:  2015-03       Impact factor: 3.017

Review 2.  Estrogen and thrombosis: A bench to bedside review.

Authors:  Mouhamed Yazan Abou-Ismail; Divyaswathi Citla Sridhar; Lalitha Nayak
Journal:  Thromb Res       Date:  2020-05-11       Impact factor: 3.944

Review 3.  Sex, stroke, and inflammation: the potential for estrogen-mediated immunoprotection in stroke.

Authors:  Rodney M Ritzel; Lori A Capozzi; Louise D McCullough
Journal:  Horm Behav       Date:  2012-04-24       Impact factor: 3.587

4.  Estrogen and estrogen receptors in kidney diseases.

Authors:  Hao-Yang Ma; Shuang Chen; Yang Du
Journal:  Ren Fail       Date:  2021-01-01       Impact factor: 2.606

5.  Thromboembolism and Oral Contraceptives During the COVID-19 Pandemic: A Disproportionality Analysis Within the Spanish Pharmacovigilance Database.

Authors:  Luis H Martín; María Sainz-Gil; Ester Navarro-García; Inés Salado-Valdivieso; Rosario Sanz-Fadrique
Journal:  Drugs Real World Outcomes       Date:  2022-02-10

6.  Life-threatening complications of hormonal contraceptives: a case history.

Authors:  Saheed Khan; Yvo M Smulders; Johanna I P de Vries; Angélique M E Spoelstra-de Man
Journal:  Case Rep Obstet Gynecol       Date:  2013-05-20

7.  Evaluation of activity of hypothalamo-pituitary-gonadal axis in postmenopausal women suffering from severe acute illness.

Authors:  M Neelima Raj; V Suresh; Arun Mukka; Amaresh Reddy; Alok Sachan; Alladi Mohan; B Vengamma; P V L N Srinivas Rao
Journal:  Indian J Med Res       Date:  2016-01       Impact factor: 2.375

8.  Impact of Severity of Illness on the Function of the Hypothalamo-pituitary-gonadal Axis in Postmenopausal Women with Acute Severe Illness: Implications for Predicting Disease Outcome.

Authors:  Suresh Vaikkakara; Marella Neelima Raj; Alok Sachan; Alladi Mohan; Bhuma Vengamma; P V L N Srinivas Rao; Arun Mukka; Chiruvella Sravani; Amaresh P Reddy
Journal:  Indian J Endocrinol Metab       Date:  2017 Sep-Oct
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.